Questions about Parkinson's disease
Short answers, pulled from the story.
What is Parkinson's disease and what causes it?
Parkinson's disease is a neurodegenerative disease primarily affecting the central nervous system, caused by the gradual loss of dopamine-producing neurons in a brain region called the substantia nigra. It has no single cause; genetic and environmental factors interact to drive the disease, including misfolded proteins called alpha-synuclein that aggregate into Lewy bodies, mitochondrial dysfunction, and neuroinflammation. About 5-10% of cases are familial, while the remaining 90% are classified as idiopathic with no clearly identifiable cause.
What are the main symptoms of Parkinson's disease?
The four cardinal motor symptoms of Parkinson's disease are tremor, bradykinesia (slowed movement), rigidity, and postural instability, collectively called parkinsonism. Non-motor symptoms are also widespread and include sleep disorders affecting up to 98% of patients, sensory deficits in up to 90%, neuropsychiatric symptoms such as anxiety, depression, and hallucinations in up to 60%, and autonomic failures like orthostatic hypotension in 30-50%. Non-motor symptoms such as depression and fatigue may contribute more to reduced quality of life than motor symptoms.
Who first described Parkinson's disease and when?
English physician James Parkinson published the first full medical description of the disease in 1817 in a monograph titled An Essay on the Shaking Palsy. He based his account on six clinical cases, including three individuals he had observed on the streets near Hoxton Square in London. French neurologist Jean-Martin Charcot later renamed the disease after Parkinson in 1877 and added bradykinesia as a fourth cardinal symptom.
How is Parkinson's disease treated?
Levodopa, which entered clinical use in 1967, is the most widely used and effective drug for Parkinson's disease and is considered the gold standard. It is typically combined with inhibitors such as carbidopa to reduce side effects. Dopamine agonists and MAO-B inhibitors are also used, particularly in earlier stages. Deep brain stimulation, developed in the late 1980s by Alim Louis Benabid and colleagues in Grenoble, France, is used when medications become ineffective. As of 2025, no disease-modifying therapies exist that can reverse or slow neurodegeneration.
How common is Parkinson's disease worldwide?
As of 2023, global prevalence of Parkinson's disease was estimated at 1.51 per 1000 people, making it the second-most common neurodegenerative disease and the fastest growing in total cases. Between 1990 and 2016, cases increased by 74%, and the number is projected to exceed 12 million by 2040. Men are approximately 1.5 times more likely to develop the disease than women, and age is the single biggest risk factor, with prevalence reaching around 4.3% in those over 85.
What role did Michael J. Fox play in raising awareness of Parkinson's disease?
Michael J. Fox was diagnosed with Parkinson's disease at age 29 and has since used his public profile to raise awareness, appearing without medication in television roles and before the United States Congress to illustrate the disease's effects. He founded the Michael J. Fox Foundation in 2000, which has raised over $2 billion for Parkinson's research. His advocacy has been credited with increasing public understanding of the disorder in the 21st century.